FUJIFILM Diosynth Biotechnologies, a world-leading contract development and manufacturing organization (CDMO) for biologics, ...

FUJIFILM has invested about $4 billion in building biopharmaceutical manufacturing sites and life sciences capabilities.

Wall Street powered to its second-best weekly advance of 2025 on Friday, with the benchmark S&P 500 (SP500) jumping nearly 5%. For the week, the S&P advanced +4 ...

Ahead of its scheduled opening later this year, the massive Fujifilm Diosynth Biotechnologies manufacturing plant in Holly ...

The agreement is valued at over $3 billion and increases U.S. manufacturing capacity to help ensure patient access to ...

Agreement secures additional U.S. manufacturing capacity to help ensure patient access to medicine HOLLY SPRINGS, N.C., April 23, 2025-- FUJIFILM Diosynth Biotechnologies, a world-leading contract ...

As pharma giants line up one after another to tout their investment plans in the U.S., Regeneron is adopting a different tack ...

FUJIFILM Diosynth Biotechnologies, a global contract development and manufacturing organization (CDMO) with major operations ...

AstraZeneca and Daiichi Sankyo are gunning to get Enhertu a new first-line approval in HER2-positive breast cancer after a ...

FUJIFILM Diosynth Biotechnologies, a world-leading contract development and manufacturing organization (CDMO) for biologics, vaccines, and advanced therapies, today announced a 10-year ...

Regeneron Pharmaceuticals Inc. agreed to pay Fujifilm Diosynth Biotechnologies more than $3 billion over the next decade to ...